Targeted Delivery of LXR Agonist Using a Site-Specific Antibody-Drug Conjugate

Bioconjugate Chemistry

Volumn 26, Issue 11, 2015, Pages 2216-2222

  Lim, Reyna K V ^a   Yu, Shan ^a   Cheng, Bo ^a   Li, Sijia ^a   Kim, Nam Jung ^b,c   Cao, Yu ^b   Chi, Victor ^a   Kim, Ji Young ^a   Chatterjee, Arnab K ^a   Schultz, Peter G ^a,b   Tremblay, Matthew S ^a   Kazane, Stephanie A ^a  

^a California Institute for Biomedical Research   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c Kyung Hee University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; BODY FLUIDS; CHEMICAL ACTIVATION; CONTROLLED DRUG DELIVERY; TARGETED DRUG DELIVERY;

ADVERSE EFFECT; ANTIBODY-DRUG CONJUGATES; CHOLESTEROL TRANSPORT; HEPATOCYTES; LIPOGENESIS; LIVER X RECEPTORS; MONOCYTE-MACROPHAGES; SITE-SPECIFIC; TARGETED DELIVERY; THERAPEUTIC POTENTIALS;

DISEASES;

AFALANINE; ANTIBODY CONJUGATE; CATHEPSIN B; CD11A ANTIBODY LIVER RECEPTOR AGONIST CONJUGATE; LIVER X RECEPTOR AGONIST; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; UNCLASSIFIED DRUG; 3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; BENZOIC ACID DERIVATIVE; BENZYLAMINE DERIVATIVE; FLUORINATED HYDROCARBON; IMMUNOGLOBULIN G; LIVER X RECEPTOR; ORPHAN NUCLEAR RECEPTOR; SULFONAMIDE; TO-901317;

ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; BINDING AFFINITY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DESIGN; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; MACROPHAGE; MONOCYTE; NONHUMAN; AGONISTS; CELL LINE; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HEP-G2 CELL LINE; IMMUNOLOGY;

ANTIGENS, CD11A; BENZOATES; BENZYLAMINES; CELL LINE; DRUG DELIVERY SYSTEMS; HEP G2 CELLS; HEPATOCYTES; HUMANS; HYDROCARBONS, FLUORINATED; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; LIVER X RECEPTORS; MACROPHAGES; MONOCYTES; ORPHAN NUCLEAR RECEPTORS; SULFONAMIDES;

EID: 84947707167     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/acs.bioconjchem.5b00203     Document Type: Article

References (44)

1. Senter, P. D. (2009) Potent antibody drug conjugates for cancer therapy Curr. Opin. Chem. Biol. 13, 235-244
2. Sievers, E. L. and Senter, P. D. (2013) Antibody-drug conjugates in cancer therapy Annu. Rev. Med. 64, 15-29
3. Ducry, L. and Stump, B. (2010) Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies Bioconjugate Chem. 21, 5-13
4. Graversen, J. H., Svendsen, P., Dagnaes-Hansen, F., Dal, J., Anton, G., Etzerodt, A., Petersen, M. D., Christensen, P. A., Møller, H. J., and Moestrup, S. K. (2012) Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone Mol. Ther. 20, 1550-1558
5. Wang, R. E., Liu, T., Wang, Y., Cao, Y., Du, J., Luo, X., Deshmukh, V., Kim, C. H., Lawson, B. R., and Tremblay, M. S. et al. 2015, An immunosuppressive antibody-drug conjugate J. Am. Chem. Soc. 137, 3229-3232
6. Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Adams, R. J., Berry, J. D., Brown, T. M., Carnethon, M. R., Dai, S., de Simone, G., and Ford, E. S. et al. 2011, Heart disease and stroke statistics - 2011 update: a report from the American Heart Association Circulation 123, e18-e209
7. Glass, C. K. and Witztum, J. L. (2001) Atherosclerosis: the road ahead Cell 104, 503-516
8. Repa, J. J., Turley, S. D., Lobaccaro, J. A., Medina, J., Li, L., Lustig, K., Shan, B., Heyman, R. A., Dietschy, J. M., and Mangelsdorf, D. J. (2000) Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers Science 289, 1524-1529
9. Janowski, B. A., Willy, P. J., Devi, T. R., Falck, J. R., and Mangelsdorf, D. J. (1996) An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha Nature 383, 728-731
10. Lehmann, J. M., Kliewer, S. A., Moore, L. B., Smith-Oliver, T. A., Oliver, B. B., Su, J. L., Sundseth, S. S., Winegar, D. A., Blanchard, D. E., and Spencer, T. A. et al. 1997, Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway J. Biol. Chem. 272, 3137-3140
11. Repa, J. J. and Mangelsdorf, D. J. (2002) The liver X receptor gene team: potential new players in atherosclerosis Nat. Med. 8, 1243-1248
12. Larrede, S., Quinn, C. M., Jessup, W., Frisdal, E., Olivier, M., Hsieh, V., Kim, M. J., Van Eck, M., Couvert, P., and Carrie, A. et al. 2009, Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent Arterioscler. Thromb. Vasc. Biol. 29, 1930-1936
13. Costet, P., Luo, Y., Wang, N., and Tall, A. R. (2000) Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor J. Biol. Chem. 275, 28240-28245
14. Pascual-Garcia, M., Carbo, J. M., Leon, T., Matalonga, J., Out, R., Van Berkel, T., Sarrias, M. R., Lozano, F., Celada, A., and Valledor, A. F. (2011) Liver X receptors inhibit macrophage proliferation through downregulation of cyclins D1 and B1 and cyclin-dependent kinases 2 and 4 J. Immunol. 186, 4656-4667
15. Zhu, Y. and Li, Y. (2009) Liver X receptors as potential therapeutic targets in atherosclerosis Clin. Invest. Med. 32, E383-394
16. Annicotte, J. S., Schoonjans, K., and Auwerx, J. (2004) Expression of the liver X receptor alpha and beta in embryonic and adult mice Anat. Rec., Part A 277, 312-316
17. Bradley, M. N., Hong, C., Chen, M., Joseph, S. B., Wilpitz, D. C., Wang, X., Lusis, A. J., Collins, A., Hseuh, W. A., and Collins, J. L. et al. 2007, Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE J. Clin. Invest. 117, 2337-2346
18. Quinet, E. M., Savio, D. A., Halpern, A. R., Chen, L., Schuster, G. U., Gustafsson, J. A., Basso, M. D., and Nambi, P. (2006) Liver X receptor (LXR)-beta regulation in LXRalpha-deficient mice: implications for therapeutic targeting Mol. Pharmacol. 70, 1340-1349
19. Lund, E. G., Peterson, L. B., Adams, A. D., Lam, M. H., Burton, C. A., Chin, J., Guo, Q., Huang, S., Latham, M., and Lopez, J. C. et al. 2006, Different roles of liver X receptor alpha and beta in lipid metabolism: effects of an alpha-selective and a dual agonist in mice deficient in each subtype Biochem. Pharmacol. 71, 453-463
20. Singhaus, R. R., Bernotas, R. C., Steffan, R., Matelan, E., Quinet, E., Nambi, P., Feingold, I., Huselton, C., Wilhelmsson, A., and Goos-Nilsson, A. et al. 2010, 3-(3-Aryloxyaryl)imidazo[1,2-a]pyridine sulfones as liver X receptor agonists Bioorg. Med. Chem. Lett. 20, 521-525
21. Travins, J. M., Bernotas, R. C., Kaufman, D. H., Quinet, E., Nambi, P., Feingold, I., Huselton, C., Wilhelmsson, A., Goos-Nilsson, A., and Wrobel, J. (2010) 1-(3-Aryloxyaryl)benzimidazole sulfones are liver X receptor agonists Bioorg. Med. Chem. Lett. 20, 526-530
22. Bernotas, R. C., Singhaus, R. R., Kaufman, D. H., Travins, J. M., Ullrich, J. W., Unwalla, R., Quinet, E., Evans, M., Nambi, P., and Olland, A. et al. 2010, 4-(3-Aryloxyaryl)quinoline sulfones are potent liver X receptor agonists Bioorg. Med. Chem. Lett. 20, 209-212
23. Collins, J. L., Fivush, A. M., Watson, M. A., Galardi, C. M., Lewis, M. C., Moore, L. B., Parks, D. J., Wilson, J. G., Tippin, T. K., and Binz, J. G. et al. 2002, Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines J. Med. Chem. 45, 1963-1966
24. Farnegardh, M., Bonn, T., Sun, S., Ljunggren, J., Ahola, H., Wilhelmsson, A., Gustafsson, J. A., and Carlquist, M. (2003) The three-dimensional structure of the liver X receptor beta reveals a flexible ligand-binding pocket that can accommodate fundamentally different ligands J. Biol. Chem. 278, 38821-38828
25. Zhao, W., Gu, Q., Wang, L., Ge, H., Li, J., and Xu, J. (2011) Three-dimensional pharmacophore modeling of liver-X receptor agonists J. Chem. Inf. Model. 51, 2147-2155
26. Hoerer, S., Schmid, A., Heckel, A., Budzinski, R. M., and Nar, H. (2003) Crystal structure of the human liver X receptor beta ligand-binding domain in complex with a synthetic agonist J. Mol. Biol. 334, 853-861
27. Li, X., Yeh, V., and Molteni, V. (2010) Liver X receptor modulators: a review of recently patented compounds (2007-2009) Expert Opin. Ther. Pat. 20, 535-562
28. Chari, R. V. (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs Acc. Chem. Res. 41, 98-107
29. Dubowchik, G. M., Mosure, K., Knipe, J. O., and Firestone, R. A. (1998) Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin Bioorg. Med. Chem. Lett. 8, 3347-3352
30. Clarke, J., Leach, W., Pippig, S., Joshi, A., Wu, B., House, R., and Beyer, J. (2004) Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody Regul. Toxicol. Pharmacol. 40, 219-226
31. Coffey, G. P., Stefanich, E., Palmieri, S., Eckert, R., Padilla-Eagar, J., Fielder, P. J., and Pippig, S. (2004) In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells J. Pharmacol. Exp. Ther. 310, 896-904
32. Coffey, G. P., Fox, J. A., Pippig, S., Palmieri, S., Reitz, B., Gonzales, M., Bakshi, A., Padilla-Eagar, J., and Fielder, P. J. (2005) Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice Drug Metab. Dispos. 33, 623-629
33. Kawamura, A., Miura, S., Murayama, T., Iwata, A., Zhang, B., Nishikawa, H., Tsuchiya, Y., Matsuo, K., Tsuji, E., and Saku, K. (2004) Increased expression of monocyte CD11a and intracellular adhesion molecule-1 in patients with initial atherosclerotic coronary stenosis Circ. J. 68, 6-10
34. Li, S., Wang, H., Peng, B., Zhang, M., Zhang, D., Hou, S., Guo, Y., and Ding, J. (2009) Efalizumab binding to the LFA-1 alphaL I domain blocks ICAM-1 binding via steric hindrance Proc. Natl. Acad. Sci. U. S. A. 106, 4349-4354
35. Axup, J. Y., Bajjuri, K. M., Ritland, M., Hutchins, B. M., Kim, C. H., Kazane, S. A., Halder, R., Forsyth, J. S., Santidrian, A. F., and Stafin, K. et al. 2012, Synthesis of site-specific antibody-drug conjugates using unnatural amino acids Proc. Natl. Acad. Sci. U. S. A. 109, 16101-16106
36. Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., and Dennis, M. S. et al. 2008, Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Nat. Biotechnol. 26, 925-932
37. Jeffrey, S. C., Burke, P. J., Lyon, R. P., Meyer, D. W., Sussman, D., Anderson, M., Hunter, J. H., Leiske, C. I., Miyamoto, J. B., and Nicholas, N. D. et al. 2013, A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology Bioconjugate Chem. 24, 1256-1263
38. Strop, P., Liu, S. H., Dorywalska, M., Delaria, K., Dushin, R. G., Tran, T. T., Ho, W. H., Farias, S., Casas, M. G., and Abdiche, Y. et al. 2013, Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates Chem. Biol. 20, 161-167
39. Werther, W. A., Gonzalez, T. N., O'Connor, S. J., McCabe, S., Chan, B., Hotaling, T., Champe, M., Fox, J. A., Jardieu, P. M., and Berman, P. W. et al. 1996, Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1 J. Immunol. 157, 4986-4995
40. Wang, L. and Schultz, P. G. (2004) Expanding the genetic code Angew. Chem., Int. Ed. 44, 34-66
41. Kularatne, S. A., Deshmukh, V., Ma, J., Tardif, V., Lim, R. K., Pugh, H. M., Sun, Y., Manibusan, A., Sellers, A. J., and Barnett, R. S. et al. 2014, A CXCR4-targeted site-specific antibody-drug conjugate Angew. Chem., Int. Ed. 53, 11863-11867
42. Hutchins, B. M., Kazane, S. A., Staflin, K., Forsyth, J. S., Felding-Habermann, B., Smider, V. V., and Schultz, P. G. (2011) Selective formation of covalent protein heterodimers with an unnatural amino acid Chem. Biol. 18, 299-303
43. Guilliams, M., Bruhns, P., Saeys, Y., Hammad, H., and Lambrecht, B. N. (2014) The function of Fcgamma receptors in dendritic cells and macrophages Nat. Rev. Immunol. 14, 94-108
44. Depis, F., Hatterer, E., Ballet, R., Daubeuf, B., Cons, L., Glatt, S., Reith, W., Kosco-Vilbois, M., and Dean, Y. (2013) Characterization of a surrogate murine antibody to model anti-human CD3 therapies MAbs 5, 555-564